Background illustration for clinical trials search

Paid Clinical Trials Calgary

Discover 521 paid clinical trials in Calgary, . Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Split Dose Polyethylene Glycol (PEG) + Clear Fluids Versus Split Dose PEG + Low-Residue Diet

for
Colorectal Cancer
Location: Calgary
Sponsor: University of Calgary

Sex: All

Age: 18 - 70+

Code: NCT01610895

Recruiting

I-Scan Vs High Definition White Light (Main Study)

for
Colorectal Cancer
Location: Calgary
Sponsor: University of Calgary

Sex: All

Age: 18 - 70+

Code: NCT02016326

Recruiting

Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy

for
Colorectal Neoplasms
Location: Calgary
Sponsor: University of Calgary

Sex: All

Age: 18 - 70+

Code: NCT05396560

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

for
Bronchiectasis With Pseudomonas Aeruginosa Colonization
Location: Calgary, Vancouver, San Francisco CA, Orange CA,
Sponsor: AstraZeneca

Sex: All

Age: 12+

Code: NCT07088926

Phase 2, Recruiting

Digital Nutrition Therapy for Patients With IBD

for
Crohn Disease, Ulcerative Colitis
Location: Calgary
Sponsor: University of Calgary

Sex: All

Age: 18 - 70+

Code: NCT04653259

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

for
Coronary Artery Disease, Heart Failure Systolic
Location: Calgary, Edmonton, Vancouver, Winnipeg, Los Angeles CA,
Sponsor: Sunnybrook Health Sciences Centre

Sex: All

Age: 18+

Code: NCT05427370

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

for
Liver Diseases, Alcoholic
Location: Calgary, New Westminster, Vancouver, Sacramento CA,
Sponsor: GlaxoSmithKline

Sex: All

Age: 18 - 70

Code: NCT06613698

Phase 2, Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis,
Location: Calgary, Vancouver, Bellevue WA, Seattle WA, Tacoma WA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18 - 70+

Code: NCT06318169

Phase 3, Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

for
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis,
Location: Calgary, Vancouver, Bellevue WA, Seattle WA, Tacoma WA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18 - 70+

Code: NCT06419374

Phase 3, Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

for
HER2-positive Gastric Cancer,
Location: Calgary, Edmonton, Reno NV, Aurora CO, Walnut Creek CA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06764875

Phase 3, Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

for
Locally Advanced Head and Neck Squamous Cell Carcinoma
Location: Calgary, Edmonton, Kelowna, Salt Lake City UT,
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT06129864

Phase 3, Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

for
B-cell Malignancies
Location: Calgary, Seattle WA, Rochester MN, La Jolla CA, Toronto,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06542250

Phase 1, Phase 2, Recruiting

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

for
Excessive Sleepiness, Shift-work Disorder
Location: Calgary, Spokane WA, Colorado Springs CO, Henderson NV,
Sponsor: Axsome Therapeutics, Inc.

Sex: All

Age: 18 - 65

Code: NCT06568367

Phase 3, Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

for
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer,
Location: Calgary, Vancouver, Santa Rosa CA, Albuquerque NM,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT05123482

Phase 1, Phase 2, Recruiting

ERAS® Guidelines Validation of CRS With or Without HIPEC

for
Peritoneal Diseases
Location: Calgary, Dallas TX
Sponsor: Hospices Civils de Lyon

Sex: All

Age: 18+

Code: NCT05185791

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

for
Weight Management
Location: Calgary, Vancouver, Victoria, Ammon ID, Arvada CO,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07667803

Phase 3, Recruiting

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

for
Large B-cell Lymphoma
Location: Calgary, Ottawa
Sponsor: AstraZeneca

Sex: All

Age: 65 - 70+

Code: NCT07215585

Phase 3, Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

for
Biliary Tract Cancer
Location: Calgary, Pierre SD, Aurora CO, Sioux Falls SD,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07221253

Phase 3, Recruiting

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

for
Relapsed AL Amyloidosis, Refractory AL Amyloidosis,
Location: Calgary, San Francisco CA, Rochester MN, Phoenix AZ,
Sponsor: Alexion Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07081646

Phase 1, Phase 2, Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

for
Endometrial Cancer
Location: Calgary, Edmonton, Eugene OR, Sioux Falls SD,
Sponsor: AstraZeneca

Sex: Female

Age: 18+

Code: NCT06989112

Phase 3, Recruiting